ITGA4 Gene Methylation Status in Chronic Lymphocytic Leukemia - Trial NCT05371392
Access comprehensive clinical trial information for NCT05371392 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Not yet recruiting. The study focuses on Chronic Lymphocytic Leukemia. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Sohag University
Timeline & Enrollment
N/A
Jul 01, 2022
Oct 01, 2023
Primary Outcome
ITGA4 gene expression pattern and its methylation heterogeneity in chronic lymphocytic leukemia
Summary
Chronic lymphocytic leukemia (CLL) is a clonal lymphoproliferative disorder that is
 characterized by heterogeneous presentation at the clinical and molecular levels. ITGA4
 protein has been found to be deregulated in CLL with adverse clinical outcome. ITGA4 gene
 (CD49d) encodes a member of the integrin alpha chain family of proteins and is considered a
 negative prognosticator in CLL with aggressive course and short time to treatment.
 
 The aim of the study:
 
 is to investigate ITGA4 gene expression pattern and to explore its methylation heterogeneity
 in CLL.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05371392
Non-Device Trial